Chimeric antigen receptor (CAR) T-cell therapy is a highly complex and innovative treatment that involves collecting and using the patients’ own immune cells to treat their cancers. In this interview we speak to M. Bilal Abid about what impact the gut microbiome could have on this immune-engaging therapy, and the regulations currently surrounding the use of probiotics.
In this interview, we speak to Jenn Edwards from the Abigail Wexner Research Institute (OH, USA) about her research using the primary human epithelial cell models to examine Neisseria gonorrhoeae infections, the potential for vaccination against gonorrhea and a possible host-targeted therapy for this infection.
In this article, we explore the crucial role of shared decision-making in HIV treatment and hear from David Hardy (Johns…
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
Sepsis, a condition associated with significant morbidity and mortality, has been increasingly associated with the gut microbiome. In this interview…
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
In this interview we speak to Pinaki Panigrahi about his work using probiotics as a preventative strategy against sepsis in neonates. In addition, he comments on the impact of probiotics for other infections and some of the skepticism surrounding some microbiome research.
What role might the healthcare environment play in infections? And how could this be mitigated? We speak to Stephanie Dancer about the healthcare environment and its role in healthcare-associated infections.
In this Ask The Experts we talk to two experts about issues surrounding healthcare-associated infections and infection prevention and control, including the role of surveillance, the involvement of patients and the importance of behavior change.
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.